Uplizna (inebilizumab-cdon) — Clinical Coverage Criteria
Customize your policy alerts
Sign up for sierra health and life Policy 2026D0091J alerts
Get alerted when Policy 2026D0091J changes without checking for updates manually.
Monitor payer policy activity
Medical policy governing clinical coverage criteria, prior authorization, and continuation requirements for Uplizna (inebilizumab-cdon) as treatment for neuromyelitis optica spectrum disorder (NMOSD), immunoglobulin G4-related disease (IgG4-RD), and generalized myasthenia gravis (gMG) for Sierra Health and Life members.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.